Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis

被引:27
|
作者
Matsuda, Kotaro [1 ,2 ]
Miyoshi, Hiroaki [1 ]
Hiraoka, Koji [2 ]
Hamada, Tetsuya [2 ]
Yoshida, Shiro [2 ]
Ishibashi, Yukinao [2 ]
Haraguchi, Toshiaki [2 ]
Shiba, Naoto [2 ]
Ohshima, Koichi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Dept Orthoped Surg, Kurume, Fukuoka, Japan
关键词
Programmed cell death 1 (PD-1); Programmed cell death ligand 1 (PD-L1); Rheumatoid arthritis (RA); Immunohistochemistry; Synovium; UP-REGULATION; INTERLEUKIN-10; ACTIVATION; RECEPTOR; PROLIFERATION; LYMPHOCYTES; PATHWAY; MEMBER; GAMMA;
D O I
10.1007/s10238-018-0515-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The etiology of rheumatoid arthritis (RA) is thought to involve dysfunction of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway; PD-1 negatively regulates autoimmunity by interacting with its ligand, PD-L1. We therefore investigated PD-1/PD-L1 expression in synovial tissue of patients with RA. We immunohistochemically stained synovial specimens from 51 patients with RA and assessed the association between PD-1/PD-L1 expression and rheumatoid factor (RF), the total count of infiltrating T cells, C-reactive protein (CRP), and Krenn's synovitis score. PD-1 expression on infiltrating lymphocytes was detected in 34/51 RA cases (66.7%), while PD-1 expression was very mildly correlated only with the number of total infiltrating T cells (R-2=0.1011, P=0.0230). On the other hand, PD-L1 expression on synovial lining cells was observed in 37/51 RA cases (72.5%). Furthermore, a higher PD-L1 expression was significantly associated with RF positive state (P=0.0454), and the correlations between PD-L1 expression and the number of infiltrating T cells (R-2=0.5571, P<0.0001), CRP (R-2=0.4060, P<0.0001), and Krenn's synovitis score (R-2=0.7785, P<0.0001) were confirmed. PD-1 was expressed on infiltrating lymphocytes, while PD-L1 was expressed on synovial lining cells; the expression of PD-L1 on synovial lining cells was significantly correlated with the active state of the disease. These data suggest that PD-1/PD-L1 pathway may have an important role in the pathogenesis of RA.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [21] Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes
    Gompertz-Mattar, Matias
    Perales, Juan
    Sahu, Aditi
    Mondaca, Sebastian
    Gonzalez, Sergio
    Uribe, Pablo
    Navarrete-Dechent, Cristian
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (08) : 777 - 786
  • [22] Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome
    Veloza, Luis
    Teixido, Cristina
    Castrejon, Natalia
    Climent, Fina
    Carrio, Ana
    Marginet, Marta
    Soldini, Davide
    Gonzalez-Farre, Blanca
    Ribera-Cortada, Inmaculada
    Lopez-Guillermo, Armando
    Gonzalez-Barca, Eva
    Sierra, Adriana
    Herrera, Mileyka
    Gomez, Candida
    Garcia, Adriana
    Balague, Olga
    Campo, Elias
    Martinez, Antonio
    HISTOPATHOLOGY, 2019, 75 (06) : 799 - 812
  • [23] Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
    Cedres, Susana
    Ponce-Aix, Santiago
    Zugazagoitia, Jon
    Sansano, Irene
    Enguita, Ana
    Navarro-Mendivil, Alejandro
    Martinez-Marti, Alex
    Martinez, Pablo
    Felip, Enriqueta
    PLOS ONE, 2015, 10 (03):
  • [24] Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
    Abbas, Mahmoud
    Steffens, Sandra
    Bellut, Maria
    Becker, Jan U.
    Grosshennig, Anika
    Eggers, Hendrik
    Wegener, Gerd
    Kuczyk, Markus A.
    Kreipe, Hans H.
    Gruenwald, Viktor
    Schrader, Andres J.
    Ivanyi, Philipp
    MEDICAL ONCOLOGY, 2016, 33 (06)
  • [25] Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population
    Yang, Q.
    Liu, Y.
    Liu, D.
    Zhang, Y.
    Mu, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 13 - 18
  • [26] Programmed cell death ligand-1 (PD-L1) expression in desmoid tumors: a retrospective study
    Yildirim, A. N. Toksoz
    Akyurek, M.
    Okay, E.
    Zenginkinet, T.
    Iyetin, Y.
    Ozkan, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (11) : 5223 - 5229
  • [27] Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol
    Wu, Lukanxuan
    Lv, Chunzi
    Su, Yifeng
    Li, Chunyan
    Zhang, Hui
    Zhao, Xinbo
    Li, Mingjiang
    GYNECOLOGICAL ENDOCRINOLOGY, 2019, 35 (03) : 251 - 256
  • [28] Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response
    Agina, Hala A.
    Ehsan, Nermine A.
    Abd-Elaziz, Taghreed A.
    Abd-Elfatah, Ghada A.
    Said, Eman M.
    Sira, Mostafa M.
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 5 (03) : 256 - 264
  • [29] Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1)
    Barbera, Angels
    Gonzalez, Juan
    Martin, Montserrat
    Mate, Jose L.
    Oriol, Albert
    Martinez-Soler, Fina
    Santalucia, Tomas
    Fernandez, Pedro Luis
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2023, 31 (09) : 607 - 612
  • [30] Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
    Mei, Yu
    Bi, Wenya Linda
    Greenwald, Noah F.
    Du, Ziming
    Agar, Nathalie Y. R.
    Kaiser, Ursula B.
    Woodmansee, Whitney W.
    Reardon, David A.
    Freeman, Gordon J.
    Fecci, Peter E.
    Laws, Edward R., Jr.
    Santagata, Sandro
    Dunn, Gavin P.
    Dunn, Ian F.
    ONCOTARGET, 2016, 7 (47) : 76565 - 76576